1 Rapid DNA methylation-based classification of pediatric brain tumours from

2 ultrasonic aspirate specimens

3

Michèle Simon^{1*}, Luis P. Kuschel^{2*}, Katja von Hoff³, Dongsheng Yuan², Pablo 4

- Hernáiz Driever¹, Elisabeth G. Hain⁴, Arend Koch⁴, David Capper^{4,5}, Matthias Schulz⁶, 5
- 6 Ulrich-Wilhelm Thomale^{6*}, Philipp Euskirchen^{2,4,5*}
- 7

8 1 Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin

- 9 and Humboldt Universität zu Berlin, Department of Pediatric Oncology and
- 10 Hematology, Berlin, Germany
- 11 2 Charité-Universitätsmedizin Berlin, Department of Neurology, Berlin, Germany
- 12 3 Department of Paediatric and Adolescent Medicine, Aarhus University Hospital,
- 13 Aarhus, Denmark
- 14 4 Charité-Universitätsmedizin Berlin, Department of Neuropathology, Berlin,
- 15 Germanv
- 16 5 German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer
- 17 Research Center (DKFZ), Heidelberg, Germany
- 18 6 Charité-Universitätsmedizin Berlin, Department of Pediatric Neurosurgery, Berlin,
- 19 Germany
- 20 *authors contributed equally
- 21
- 22 Corresponding Author:
- 23 Philipp Euskirchen, MD
- 24 Department of Neuropathology
- Charité Universitätsmedizin Berlin 25
- 26 Charitéplatz 1
- 27 10117 Berlin
- 28 Germany
- 29 E-Mail: philipp.euskirchen@dkfz.de
- 30
- 31
- 32 Keywords:
- 33 nanopore sequencing, pediatric brain cancer, ultrasonic aspirator NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

3435 Abstract

36

Background: Although cavitating ultrasonic aspirators are commonly used in neurosurgical procedures, the suitability of ultrasonic aspirator-derived tumor material for diagnostic procedures is still controversial. Here, we explore the feasibility of using ultrasonic aspirator-resected tumor tissue to classify otherwise discarded sample material by fast DNA methylation-based analysis using low pass nanopore whole genome sequencing.

43 Methods: ultrasonic aspirator-derived specimens from pediatric patients undergoing 44 brain tumour resection were subjected to low-pass nanopore whole genome 45 sequencing. DNA methylation-based classification using a neural network classifier 46 and copy number variation analysis were performed. Tumor purity was estimated 47 from copy number profiles. Results were compared to microarray (EPIC)-based 48 routine neuropathological histomorphological and molecular evaluation.

49 **Results:** 18 samples with confirmed neuropathological diagnosis were evaluated. All 50 samples were successfully sequenced and passed quality control for further analysis. 51 DNA and sequencing characteristics from ultrasonic aspirator-derived specimens 52 were comparable to routinely processed tumor tissue. Classification of both methods 53 was concordant regarding methylation class in 16/18 (89%) cases. Application of a 54 platform-specific threshold for nanopore-based classification ensured a specificity of 55 100%, whereas sensitivity was 78%. Copy number variation profiles were generated for all cases and matched EPIC results in 16/18 (89%) samples, even allowing the 56 57 identification of diagnostically or therapeutically relevant genomic alterations.

58 **Conclusion**: Methylation-based classification of pediatric CNS tumors based on 59 ultrasonic aspirator-reduced and otherwise discarded tissue is feasible using time-60 and cost-efficient nanopore sequencing.

61

62 63 Introduction

64

65 Ultrasonic aspirator devices are frequently used in pediatric neurosurgery for efficient 66 microsurgical resection of brain tumours while minimizing tissue damage to 67 surrounding healthy brain (1). With ultrasonic aspirator, tumor tissue is fragmented in situ by ultrasound-induced vibration and tissue debris is aspirated using suction. To 68 69 date, ultrasonic aspirator tissue specimens have not been used for routine 70 neuropathological examinations. At the same time, molecular profiling is increasingly 71 used and required in addition to histomorphology for diagnostic workup and 72 comprehensive characterization of pediatric brain tumours (2). In particular molecular 73 classification based on DNA methylation signatures has proven to be a powerful and 74 elegant unbiased approach to identifying tumor type (3) and has been adopted in the 75 current World Health Organization (WHO) classification of central nervous system 76 (CNS) tumours (4). For DNA extraction, however, additional tissue is needed which 77 may be scarce in pediatric neurosurgery. While for histological examination it 78 appears necessary to preserve the integrity of the tissue, DNA methylation profiling 79 (as any nucleic acid-based method) only relies on the integrity of tumor DNA. 80 Repurposing ultrasonic aspirator tissue specimens as a source of tumor DNA for 81 molecular diagnostics would maximize use of tumor tissue. To date, only detection of 82 focal amplifications (5) and gene expression profiling by RNA sequencing (6) in 83 ultrasonic aspirator tissue samples have been explored.

84 The growth patterns of pediatric brain tumors differ from those of adult tumors in that 85 they are more likely to spread in the neuraxis (7). Furthermore, highly aggressive 86 rare embryonal and sarcomatous pediatric CNS tumors for which there are limited 87 therapeutic recommendations and for which immediate initiation of therapy is essential have only recently been molecularly redefined (8). The overall time to 88 89 integrated diagnosis in pediatric oncology is therefore of considerable importance, 90 and any delay in initiating first-line therapy may be critical. Indeed, the presence of 91 molecular markers defining risk groups in therapy trials also leads to different 92 therapeutic approaches.

Recently, we have demonstrated, that low-pass nanopore whole genome sequencing
(WGS) is non-inferior to microarray-based DNA methylation profiling of CNS tumors
(9). In addition, real-time analysis is feasible, enabling a reliable intraoperative

diagnosis within a surgically relevant time frame at low cost (10). In addition, adaptive
sequencing allows to enrich genomic regions of interest in the same WGS run to
detect clinically relevant SNV and SV (11).

99 In the present study, we studied whether DNA methylation-based classification can 100 be reliably performed using DNA from tumor tissue fragments obtained by ultrasonic 101 aspirator devices using low-pass nanopore whole genome sequencing in order to 102 overcome time-consuming tissue processing and maximize use of limited material in 103 pediatric neuro-oncology.

104

105 Methods

106

107 Study design

108 We conducted a prospective, proof-of-concept single-center study using ultrasonic 109 aspirator tissue specimens for molecular characterization of pediatric CNS tumors 110 using nanopore WGS (Fig. 1 (A)). All patients < 18 years who underwent surgery for 111 tumor resection using an ultrasonic aspiration device at the Department of Pediatric 112 Neurosurgery, Charité-Universitätsmedizin Berlin, Germany, between February 6th, 113 2020, and October 5th, 2020, were screened. Informed written consent was obtained from patients and/or guardians. The study was approved by the local ethics 114 committee (Charité –Universitätsmedizin Berlin, Berlin, Germany; EA2/041/18) and 115 performed according to the guidelines for Good Scientific Practice. Ultrasonic 116 117 aspirator tissue samples taken with the LEVICS device (Söring, Quickborn, 118 Germany), which are normally discarded after surgery, are collected using a 119 bronchoalveolar lavage trap, which is connected to the suction tubing coming from 120 the sonotrode instruments and connected to the suction reservoir. Thereby about 5ml 121 of fluid including fragmented tumor tissue could be collected. In parallel, regularly 122 resected umor tissue was processed for routine neuropathological procedures 123 including phenotypic-genotypic diagnostics. All study data were archived under an ID 124 key accessible only to the research group (pseudonymization). Pseudonymized study 125 data were recorded using REDCap (13), which was provided by the Berlin Institute of 126 Health's Clinical Research Unit in a certified computing environment.

127

128 Ultrasonic aspirator tissue sample processing

Fresh ultrasonic aspiratior fluid aliquots were centrifuged at 1.000 rpm for 5 min,supernatant was discarded and pellets stored at -40°C. DNA was extracted from ~25 mg thawed aspirate and purified using the DNeasy Blood & Tissue Kit (Qiagen, NL). Based on the 260/280 ratio (NanoDrop, Thermo Fisher, USA), DNA quality was determined, followed by DNA quantification with a Qubit 4.0 fluorometer using a dsDNA BR Assay (Thermo Fisher, USA).

135

136 Nanopore low-pass whole genome sequencing

137 All samples were subjected to low-pass whole genome sequencing as described 138 previously (9). Preprocessing of raw data for sequencing was performed using the 139 publicly available nanoDx pipeline (<u>https://gitlab.com/pesk/nanoDx</u>, v0.5.1). Briefly, 140 basecalling of nanopore FAST5 raw data was performed using guppy v5.0.16 141 (Oxford Nanopore Technologies, UK) and aligned to the hg19 human reference 142 genome using minimap2 v2.15 (14). In order to assess the feasibility of ultrasonic 143 aspirator-derived nanopore sequencing, the aligned sequencing data was normalized 144 to a six hour sequencing window and were compared to a previously published 145 dataset of 16 brain tumor samples obtained during routine nanopore sequencing 146 from fresh-frozen tumor tissue (9). DNA methylation was assessed using nanopolish 147 v0.11.1 (15). After binarization of beta values with threshold = 0.6 (9), features with 148 zero variance were filtered out, leading to 366,263 CpG sites retained. These were 149 used to train the neural network model with randomly masked features. PyTorch, an 150 open source deep-learning framework, was used to develop the model (16). To 151 obtain class probability estimates that can be used to guide diagnostic decision-152 making, a normalization function and a Softmax layer was used to convert the raw 153 values into a probability that measures the confidence in the brain tumor class 154 assignment (the calibrated score). Returned majority votes were combined to methylation class families (MCF), if feasible (9). Complementarily, data was 155 156 displayed using t-distributed Stochastic Neighborhood Embedding (t-SNE) (17).

157

158 CNS tumor classification

All cases were classified according to the 2016 WHO CNS classification during routine neuropathological examination at the Department of Neuropathology, Charité Universitätsmedizin Berlin. The recent 2021 edition (4) was not yet available during the study period of this patient cohort. Nanopore classification results were compared

163 to the reference diagnosis as well as microarray-based classification results of the 164 same tumor considering the established cut-off values for the probability score.

165

166 Copy number analysis

167 Copy number variation (CNV) analysis from nanopore WGS data was performed 168 using the QDNAseg package v1.8.0 and R/Bioconductor v3.3 as described before 169 (18, 19). To account for region- and technology-specific artifacts, public nanopore 170 WGS data for the NA12878 human reference genome were processed and 171 subtracted from the normalized bin counts of the tumor samples for case reports. To estimate tumor purity in aneuploid tumors, absolute copy number estimation of 172 173 nanopore- and microarray-based data was performed using the ACE software 174 package (v1.6.0) (20). All estimates were verified manually.

175

176 Methylation array processing

177 Infinium MethylationEPIC BeadChip microarrays (Illumina) were used to obtain 178 genome-wide DNA methylation profiles for tumor samples during routine 179 neuropathological diagnostic examination. Data were generated following the 180 manufacturer's protocol at the Department of Neuropathology, Charité -181 Universitätsmedizin Berlin, using >250 ng of DNA from FFPE tissues as input 182 material. For classification, IDAT files were uploaded to the public Heidelberg brain 183 tumour classifier available at <u>https://www.molecularneuropathology.org</u> (v.11b4).

184 Statistical analysis

185 Reproducible and easy-to-deploy pipelines were implemented using snakemake
186 (v.7.15.2) (21). Data analysis was mainly performed using R (v.4.0.2). Figures were
187 designed using ggplot2 (v.3.3.2). Statistical analyses were performed using IBM
188 SPSS[®] 29 (Armonk, N.Y., USA)

189

190 Data and code availability

191 The nanoDx analysis pipeline for end-to-end analysis of nanopore WGS data is 192 available at https://gitlab.com/pesk/nanoDx (v.0.5.1). Source code to reproduce all 193 analyses and sequencing data based figures in this work is provided at 194 https://gitlab.com/pesk/nanoCUSA. Raw sequencing data have been deposited at the 195 European Genome-phenome archive (accession no. tbd), while methylation

196 microarray data and nanopore methylation calls are available from Gene Omnibus197 Express (accession no. tbd).

198

199 Results

200

201 Patient characteristics

202 A total of 21 children undergoing surgery participated in the study. 3/21 (14.9%) of 203 patients were excluded from analysis due to non-diagnostic scores in microarray-204 based classification (n=2) or final diagnosis of non-neoplastic disease (n=1). 205 Eventually, our cohort comprised 18 tumor aspirates from 18 pediatric patients (Table 206 1). 33% of patients (n=6) were male. Median age at surgery was 7.5 years (range 1 207 to 17 years). Twelve patients suffered from a newly diagnosed cerebral lesion, 208 whereas six samples were obtained from a second or further intervention. Five 209 patients had received previous treatment with vincristine/carboplatin according to the 210 European auidelines for low-grade alioma (LGG) (n=4) or 211 cyclophosphamide/vincristine/methotrexate/carboplatin/etoposide according to the 212 current treatment recommendation of the German Society of Pediatric Oncology and 213 Hematology (GPOH) for newly diagnosed medulloblastoma, ependymoma, and 214 pineoblastoma (n=1). One patient with LGG was previously treated with vinblastine 215 monotherapy and targeted therapy using a MEK inhibitor. The most frequent 216 diagnosis was pilocytic astrocytoma (50%, n=9).

217

218 Sequencing characteristics of tumor DNA from ultrasonic aspirator tissue219 samples

220 Low-pass whole genome sequencing performed for at least 6 hours resulted in a 221 mean genome coverage of 0.44X (range 0.01X to 1.5X, Suppl. Table 1). The mean 222 read length ranged between 4,047 and 10,440 base pairs with a mean of 7,377 base 223 pairs and was comparable to reads obtained in an external cohort of sequencing runs 224 of tumor DNA extracted from fresh-frozen tissue (Fig. 1B). The mean number of CpG 225 sites overlapping the reference atlas was 100,852 CpGs (range: 2,275 to 295,872 226 CpG sites), exceeding the minimum number of 1,000 overlapping CpG sites for 227 meaningful analysis in 18/18 (100%) samples. In two cases, the minimum number of 228 CpG sites was not achieved initially and required an additional sequencing run. On 229 average, after six hours of sequencing 1,054 Mb of aligned base pairs were obtained

(range: 23.76 Mb - 2299.12 Mb), which again was comparable to sequencing runs
from fresh-frozen tissue (Fig. 1C). Tumor cell content was reliably estimated from
copy number alterations in 4/20 (20%) tumors with a mean tumor purity of 0.37
(range 0.25 – 0.65) (Fig. 1D). Tumor purity was higher in ultrasonic aspirator tissue
samples compared to FFPE tissue for routine workup in 3 out of 4 (75%) cases.

235

236 DNA methylation-based classification

237 Tumors were classified based on DNA methylation profiles using a neural network 238 model which had been trained using the Heidelberg brain tumour reference cohort 239 with CNS tumor methylation datasets of 2,801 samples and predictions were made 240 with respect to the 91 methylation classes (MC) or methylation class family (MCF), 241 respectively, as defined in the 11b4 version (3). A single nanopore-specific cut-off 242 value was determined by recalibrating the raw values to identify valid predictions. 243 Receiver operating characteristic curve analysis of the maximum calibrated scores 244 was used to determine an optimal cut-off value > 0.2.

Classification results were identical to microarray in 16/18 (89%) of cases and compatible with the integrative histopathological reference diagnosis in 16/18 (89%) cases (Figure 2). Application of the optimal calibrated score threshold of >0.2 resulted in 14/18 cases passing the cut-off all of which were correctly classified, corresponding to a specificity of 100% and a sensitivity of 78% on both MC and MCF level (Figure 2).

251 At the MC level, in 2/18 (11%) cases, the score was below the optimal threshold but 252 classification was still correct (one YAP-fusion positive ependymoma, one 253 subependymal giant-cell astrocytoma (SEGA)). 2/18 (11%) cases had discordant 254 results with scores that were below the calibrated nanopore-specific threshold: In the 255 first case, pilocytic astrocytoma (PA) subtype was incorrect (classifying the case as 256 midline PA instead of posterior fossa PA) while correctly classifying the sample as PA 257 on MCF level. The other sample was an IDH-mutant astrocytoma classified as control 258 tissue. Here, additional Sanger sequencing revealed no IDH mutation in the 259 ultrasonic aspirator tissue sample, potentially indicating a sampling issue.

For comparison, the microarray-based analysis from matched FFPE tissue yielded a diagnostic score in 16/18 (89%) cases. Of note, the two cases with nondiagnostic score included one case of SEGA that also received a low score in nanopore/ultrasonic aspirator tissue profiling.

264

265 Copy number profiling

266 Copy number profiles obtained from WGS closely resembled matched array-based 267 profiles in 16/18 (88.9 %) cases and enabled the detection of large chromosomal 268 alterations, whereas two nanopore-based CNVs (both pilocytic astrocytomas) were 269 insufficient for interpretation (Suppl. Figure 1). In contrast, low-level focal gains such 270 as tandem duplications resulting in BRAF fusion genes in the PA samples were 271 visually identified in 1/9 (11.1 %) cases from nanopore CNV profiles compared with 272 detection in 8/9 (88.8 %) in matched CNV profiles from methylation microarrays 273 (Suppl. Figure 1).

274

275 Discussion

276

277 Molecular testing is an essential component of state-of-the-art integrated 278 neuropathological diagnostics for most pediatric brain tumor types. Due to the 279 increasing number of pathological examinations required (such as DNA and RNA 280 gene panel sequencing or methylation microarray), tissue is valuable. This proof-of-281 principle study reports, to our knowledge, the first application of ultrasonic aspirator-282 derived tumor tissue for molecular classification of pediatric CNS tumors using low-283 pass nanopore whole genome sequencing. We show that ultrasonic aspirator-derived 284 tumor fragments are a representative source of tumor DNA with tumor cell content 285 sufficient to DNA methylation-based classification and yielding identical classification 286 results.

287

288 Tissue characteristics

Although the use of ultrasonically minced tumor tissue for histopathological analysis of brain tumor tissue has been demonstrated in some studies, the suitability is still matter of debate (23-26). In particular, the grading of glial tumors has been reported difficult as histomorphology was only partly recapitulated.

Using read length distribution of mapped nanopore reads as a proxy of DNA fragment length, we find no significant difference in DNA extracted from fresh ultrasonic aspirator tissue aspirates compared to routinely prepared fresh-frozen tissue. Our analysis thus confirms that high molecular weight genomic DNA suitable for nanopore sequencing can be extracted when ultrasonic aspirator-derived tissue is

used. Additionally, similar aligned base yields indicate comparable sequencing performance. Tumor purity estimations for microarray and nanopore indicate a tendency towards higher tumor purity in ultrasonic aspirator tissue samples. However, the estimation depends on the existence of numerical chromosomal alterations. As expected, the majority of cases within a pediatric cohort are pilocytic astrocytomas which lack relevant aneuploidy. Therefore, tumor purity could only be determined in 4 cases.

305 One of the major advantages of using ultrasonic aspirator tissue samples is that 306 multiple areas of the excised tumor are sampled (23). This is particularly important 307 because analyses based on single biopsies may have potential consequences for 308 treatment decisions in spatially and temporally heterogeneous pediatric tumors (27, 309 28). In contrast, DNA extraction for methylome profiling is usually done after 310 microdissection of a representative area of the tumor sample with an anticipated 311 tumor cell content of \geq 70% and therefore reflects only a subset of the entire tumor 312 (3).

313

314 Comparison to microarray-based classification

315 It was recently demonstrated, that the application of nanopore technology can be used with comparable reliability for processing of fresh frozen tissue compared to 316 317 microarray-based analysis of FFPE material (9). Our analysis confirms its suitability when using ultrasonic aspirator-derived tissue. Similar to the observed sensitivity of 318 319 88% in a well-defined validation cohort for microarray-based classification (3), our 320 approach reaches an overall accuracy of 89% and a sensitity of 78% for the > 0.2321 cut-off while retaining 100% specificity. In contrast, in a real-world cohort enriched for 322 challenging cases a sensitivity as low as 56% was reported for EPIC-based 323 microarray analysis (29).

Especially low-tumor cell content, like in the infiltration zone of diffuse glioma, can be challenging for the performance of DNA methylation-based classification (30) and was likely the cause for the discordantly classified cases (before application of diagnostic cut-offs) in this cohort. Therefore, low tumor cell content poses a challenge to methylation-based classification in general, independent of the processed tissue type or technology platform used for methylome profiling.

330 Copy number profiles can be derived both from nanopore low-pass WGS and 331 methylation microarray datasets. While the resolution of microarray-based CNV plots

is fixed due to the probe set of the chip, resolution of low-pass WGS-based CNV plots correlates with read yield. In our cohort, the quality of nanopore CNV plots was frequently inferior to the matched microarray-based ones. However, next generation flow cells and chemistries for nanopore sequencing devices offer better yields and are likely to resolve these issues.

337

338 Conclusion

339 DNA methylation-based classification of pediatric CNS tumors from ultrasonic 340 aspirator-fragmented tissue is feasible using nanopore sequencing. A neural network 341 classifier with nanopore-specific diagnostic score thresholds assures high specificity 342 while achieving acceptable sensitivity. Generation of CN profiles is possible and 343 allows for detection of chromosomal changes, but was currently inferior in detection 344 of focal changes (e.g. BRAF tandem duplication) compared to microarray 345 approaches. This approach allows maximum exploitation of available tissue for 346 diagnostics. Since advanced molecular techniques have limited benefit for patients in 347 ressource-challenged centers, our time- and cost-efficient approach may be of 348 particular interest.

349

350 Acknowledgments

We thank Aydah Sabah for expert technical assistance. Computation has been performed on the HPC for Research cluster of the Berlin Institute of Health. P.E. has been a participant in the BIH-Charité Clinical Scientist Program funded by the Charité – Universitätsmedizin Berlin and BIH.

Figures were created in part using Servier Medical Art provided by Servier and licensed under a Creative Commons Attribution 3.0 unported license. In addition, images illustrating nanopore sequencing were reproduced with permission from Oxford Nanopore Technologies Plc, United Kingdom.

359

360 Conflicts of interest

361 PHD is ICI of the Sprinkle study and advisory board member for Alexion. DC declares
362 a patent for a method to classify tumors according to DNA methylation signature. All

- 363 other authors declare no conflicts of interest.
- 364

365 **References**

medRxiv preprint doi: https://doi.org/10.1101/2023.10.25.23297418; this version posted October 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

366

Zebian B, Vergani F, Lavrador JP, Mukherjee S, Kitchen WJ, Stagno V, et al.
 Recent technological advances in pediatric brain tumor surgery. CNS Oncol.
 2017;6(1):71-82.

Sturm D, Capper D, Andreiuolo F, Gessi M, Kolsche C, Reinhardt A, et al.
 Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology.
 Nat Med. 2023;29(4):917-26.

373 3. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA 374 methylation-based classification of central nervous system tumours. Nature. 375 2018;555(7697):469-74.

4. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al.
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
Neuro Oncol. 2021;23(8):1231-51.

5. Truong LN, Patil S, Martin SS, LeBlanc JF, Nanda A, Nordberg ML, et al. Rapid detection of high-level oncogene amplifications in ultrasonic surgical aspirations of brain tumors. Diagn Pathol. 2012;7:66.

382 6. Alenda C, Rojas E, Valor LM. FFPE samples from cavitational ultrasonic 383 surgical aspirates are suitable for RNA profiling of gliomas. PLoS One. 384 2021;16(7):e0255168.

385 7. Merchant TE, Pollack IF, Loeffler JS. Brain tumors across the age spectrum:
386 biology, therapy, and late effects. Semin Radiat Oncol. 2010;20(1):58-66.

387 8. Gojo J, Kjaersgaard M, Zezschwitz BV, Capper D, Tietze A, Kool M, et al.
388 Rare embryonal and sarcomatous central nervous system tumours: State-of-the art
389 and future directions. Eur J Med Genet. 2023;66(1):104660.

390 9. Kuschel LP, Hench J, Frank S, Hench IB, Girard E, Blanluet M, et al. Robust
391 methylation-based classification of brain tumours using nanopore sequencing.
392 Neuropathol Appl Neurobiol. 2022:e12856.

393 10. Djirackor L, Halldorsson S, Niehusmann P, Leske H, Capper D, Kuschel LP, et
394 al. Intraoperative DNA methylation classification of brain tumors impacts
395 neurosurgical strategy. Neurooncol Adv. 2021;3(1):vdab149.

396 11. Patel A, Dogan H, Payne A, Krause E, Sievers P, Schoebe N, et al. Rapid397 CNS(2): rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a
398 proof-of-concept study. Acta Neuropathol. 2022;143(5):609-12.

- Branton D, Deamer DW, Marziali A, Bayley H, Benner SA, Butler T, et al. The
 potential and challenges of nanopore sequencing. Nat Biotechnol. 2008;26(10):114653.
- 402 13. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
 403 electronic data capture (REDCap)--a metadata-driven methodology and workflow
 404 process for providing translational research informatics support. J Biomed Inform.
 405 2009;42(2):377-81.
- 406 14. Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics. 407 2018;34(18):3094-100.
- 408 15. Simpson JT, Workman RE, Zuzarte PC, David M, Dursi LJ, Timp W. Detecting 409 DNA cytosine methylation using nanopore sequencing. Nat Methods. 410 2017;14(4):407-10.
- 411 16. Paszke A, Gross S, Massa F, Lerer A, Bradbury J, Chanan G, et al. Pytorch:
 412 An imperative style, high-performance deep learning library. Advances in neural
 413 information processing systems. 2019;32.
- 414 17. van der Maaten L; Hinton G. Visualizing data using t-sne. Journal of Machine 415 Learning Research, 9(Nov):2579–2605, 2008.

medRxiv preprint doi: https://doi.org/10.1101/2023.10.25.23297418; this version posted October 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

416 18. Euskirchen P, Bielle F, Labreche K, Kloosterman WP, Rosenberg S, Daniau
417 M, et al. Same-day genomic and epigenomic diagnosis of brain tumors using real418 time nanopore sequencing. Acta Neuropathol. 2017;134(5):691-703.

419 19. Scheinin I, Sie D, Bengtsson H, van de Wiel MA, Olshen AB, van Thuijl HF, et
420 al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow
421 whole-genome sequencing with identification and exclusion of problematic regions in
422 the genome assembly. Genome Res. 2014;24(12):2022-32.

423 20. Poell JB, Mendeville M, Sie D, Brink A, Brakenhoff RH, Ylstra B. ACE: 424 absolute copy number estimation from low-coverage whole-genome sequencing 425 data. Bioinformatics. 2019;35(16):2847-9.

426 21. Koster J, Rahmann S. Snakemake--a scalable bioinformatics workflow engine.
427 Bioinformatics. 2012;28(19):2520-2.

428 22. Moudgil-Joshi J, Kaliaperumal C. Letter regarding Louis et al: The 2021 WHO
429 Classification of Tumors of the Central Nervous System: A summary. Neuro Oncol.
430 2021;23(12):2120-1.

431 23. Rao S, Vazhayil V, Nandeesh BN, Beniwal M, Rao K, Yasha TC, et al.
432 Diagnostic Utility of CUSA Specimen in Histopathological Evaluation of Tumors of
433 Central Nervous System. Neurol India. 2020;68(6):1385-8.

434 24. Finley JL, Silverman JF, Dickens MA. Immunocytochemical evaluation of
435 central nervous system tumors obtained by the Cavitron ultrasonic surgical aspirator.
436 Diagn Cytopathol. 1990;6(5):308-12.

437 25. Silverman JF, Jones FD, Unverferth M, Berns L. Cytopathology of neoplasms
438 of the central nervous system in specimens obtained by the Cavitron Ultrasonic
439 Surgical Aspirator. Acta Cytol. 1989;33(5):576-82.

440 26. Richmond IL, Hawksley CA. Evaluation of the histopathology of brain tumor
441 tissue obtained by ultrasonic aspiration. Neurosurgery. 1983;13(4):415-9.

Schmelz K, Toedling J, Huska M, Cwikla MC, Kruetzfeldt LM, Proba J, et al.
Spatial and temporal intratumour heterogeneity has potential consequences for
single biopsy-based neuroblastoma treatment decisions. Nat Commun.
2021;12(1):6804.

446 28. Lazow MA, Hoffman L, Schafer A, Osorio DS, Boue DR, Rush S, et al.
447 Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas. Acta
448 Neuropathol Commun. 2020;8(1):182.

449 29. Jaunmuktane Z, Capper D, Jones DTW, Schrimpf D, Sill M, Dutt M, et al.
450 Methylation array profiling of adult brain tumours: diagnostic outcomes in a large,
451 single centre. Acta Neuropathol Commun. 2019;7(1):24.

452 30. Capper D, Stichel D, Sahm F, Jones DTW, Schrimpf D, Sill M, et al. Practical 453 implementation of DNA methylation and copy-number-based CNS tumor diagnostics:

454 the Heidelberg experience. Acta Neuropathol. 2018;136(2):181-210.

455

456 457 **Figure legends**

458

459 Figure 1: (A) Overview of the study design including workflow using ultrasonic 460 aspirator tissue specimens for nanopore sequencing for DNA methylation-based classification using a neural network classifier and copy number variation analysis, 461 462 comparison to microarray-based routine neuropathological profiling and assessment of tumor purity by absolute copy number estimation using ACE. Suitability of 463 464 ultrasonic aspirator-derived tumor tissue (UA) for nanopore sequencing (T-Test and 465 Mann-Whitney U with P > .05): (B,C) Comparison of (B) mean read length and (C) 466 read yield obtained from standard nanopore protocol using fresh-frozen (FrFr) tumor 467 tissue vs. ultrasonic aspirator-derived sample material indicates similar sequencing 468 performance. (D) In silico tumor purity estimation between nanopore ultrasonic aspirator tissue samples and microarray FFPE tissue. (E,F) Representative 469 470 illustration of matched copy number variation profiles obtained from (E) ultrasonic 471 aspirator tissue samples and nanopore sequencing and (F) FFPE tumor tissue 472 subjected to EPIC microarray (850K). Red marker indicates a low-level gain of the 473 BRAF locus suggestive of a BRAF gene fusion.

474

475 Figure 2: Nanopore classification methylation class call of ultrasonic aspirator476 derived tumor material and the corresponding 2016 WHO CNS reference diagnosis
477 results showing a specificity of 100% and sensitivity of 77.7 % for cases above the
478 calibrated threshold of > 0.2.

479

480 Suppl. Figure 1: Comparison of copy number variation profiles obtained from (A)
481 ultrasonic aspirator tissue samples and nanopore sequencing and (B) FFPE tumor
482 tissue subjected to EPIC microarray (850K).

483

484 **Table 1:** Overview of the patient cohort.

485

486

487

488





	Reference diagnosis	Nanopore MC	Classification score	Concordance
A)	Anaplastic Ependymoma (1)	EPN, PF A (1)		
	Atypical central neurocytoma (1)	CN (1)		
	CNS neuroblastoma (1)	CNS NB, FOXR2 (1)		
	Craniopharyngioma (1)	CPH, ADM (1)		
	Ependymoma, RELA fusion-positive (1)	EPN, RELA (1)		
		LGG, PA MID (1)	score > 0.2 (14)	Concordant (14)
	Pilocytic astrocytoma (8)	LGG, PA PF (7)		
	Schwannoma (1)	SCHW (1)		
(B)	Ependymoma (1)	EPN, YAP (1)	score < 0.2 (2)	Concordant (2)
	Subependymal giant cell astrocytoma (1)	LGG, SEGA (1)		(-)
(C)				
(C)	Diffuse astrocytoma, IDH-mutant (1)	CONTR, HEMI (1)	score < 0.2 (2)	Discordant (2)
	Pilocytic astrocytoma (1)	LGG, PA MID (1)		

Ultrasonic aspirator I DX-BLN-025



(B)

Microarray I DX-BLN-025























































































































Patient	Sex	CNS WHO 2016	Microarray	Probability	Nanopore	tSNE	Nanopore	tSNE
ID			methylation class	score	methylation class	methylation	methylation class	methylation
					family	class family		class
						concordance		concordance
DX-	F	CNS	CNS neuroblastoma	0,682	CNS neuroblastoma	+	CNS neuroblastoma	+
BLN-		neuroblastoma	with FOXR2		with FOXR2		with FOXR2	
025			activation	0.054	activation		activation	
DX-		Schwannoma	schwannoma	0,854	schwannoma	+	schwannoma	+
BLN-								
027		Dilografia	low grado glioma	0 5 8 2	nilogutio		lour grada gliama	
		astrocytoma	subclass postorior	0,565	astrocytic	–	subclass postorior	Ŧ
028		astrocytoma	fossa pilocytic		astrocytoma		fossa nilocytic	
020			astrocytoma				astrocytoma	
אם-	F	Enendymoma	ependymoma YAP	0 101	glioblastoma IDH	+	ependymoma YAP	+
BIN-	'		fusion	0,101	wildtyne	·	fusion	
029								
DX-	F	Pilocytic	low grade glioma,	0,539	pilocytic	+	low grade glioma,	+
BLN-		astrocytoma	subclass posterior		astrocytoma		subclass posterior	
037			fossa pilocytic				fossa pilocytic	
			astrocytoma				astrocytoma	
DX-	F	Pilocytic	low grade glioma,	0,557	pilocytic	+	low grade glioma,	+
BLN-		astrocytoma	subclass posterior		astrocytoma		subclass posterior	
042			fossa pilocytic				fossa pilocytic	
			astrocytoma				astrocytoma	
DX-	M	Ependymoma,	ependymoma, RELA	0,428	ependymoma, RELA	+	ependymoma, RELA	+
BLN-		RELA fusion-	fusion		fusion		fusion	
043		positive						
DX-	F	Pilocytic	low grade glioma,	0,5	pilocytic	+	low grade glioma,	+
BLN-		astrocytoma	subclass posterior		astrocytoma		subclass posterior	
047			tossa pilocytic				tossa pilocytic	
			astrocytoma				astrocytoma	
DX-	M	Anaplastic	ependymoma,	0,754	ependymoma,	+	ependymoma,	+

BLN-		Ependymoma	posterior fossa		posterior fossa		posterior fossa	
048			group A		group A		group A	
DX-	F	Pilocytic	low grade glioma,	0,12	pilocytic	-	low grade glioma,	-
BLN-		astrocytoma	subclass posterior		astrocytoma		subclass midline	
049			fossa pilocytic				pilocytic	
			astrocytoma				astrocytoma	
DX-	F	Atypical central	central	0,721	central	+	central	+
BLN-		neurocytoma	neurocytoma		neurocytoma		neurocytoma	
050								
DX-	F	Diffuse	IDH glioma,	0,166	pilocytic	-	control tissue,	-
BLN-		astrocytoma, IDH-	subclass		astrocytoma		hemispheric cortex	
054		mutant	astrocytoma					
DX-	F	Subependymal	#NV	0,15	low grade glioma,	-	low grade glioma,	-
BLN-		giant cell			subependymal		subependymal	
064		astrocytoma			giant cell		giant cell	
					astrocytoma		astrocytoma	
DX-	М	Pilocytic	low grade glioma,	0,472	pilocytic	+	low grade glioma,	+
BLN-		astrocytoma	subclass posterior		astrocytoma		subclass posterior	
065			fossa pilocytic				fossa pilocytic	
			astrocytoma				astrocytoma	
DX-	F	Pilocytic	#NV	0,485	pilocytic	+	low grade glioma,	+
BLN-		astrocytoma			astrocytoma		subclass midline	
071							pilocytic	
							astrocytoma	
DX-	М	Craniopharyngioma	craniopharyngioma,	0,555	craniopharyngioma,	+	craniopharyngioma,	+
BLN-			adamantinomatous		adamantinomatous		adamantinomatous	
073								
DX-	М	Pilocytic	low grade glioma,	0,691	pilocytic	+	low grade glioma,	+
BLN-		astrocytoma	subclass posterior		astrocytoma		subclass posterior	
074			fossa pilocytic				fossa pilocytic	
			astrocytoma				astrocytoma	
DX-	Μ	Pilocytic	low grade glioma,	0,405	pilocytic	+	low grade glioma,	+
BLN-		astrocytoma	subclass posterior		astrocytoma		subclass posterior	

075	fossa piloc	cytic	fossa	pilocytic	
	astrocyton	ma	astro	cytoma	